title: Treating severe sepsis with drotrecogin alfa (activated).
abstract: Severe sepsis is a complex condition with mortality rates ranging from 30 to 50% in spite of advances in critical care. Xigris (drotrecogin alfa (activated)) is associated with an absolute reduction in the risk of death of 6.1% and was granted European Union marketing authorization in August 2002.
authors.affiliation: St Thomas' Hospital, London SE1 7EH.
authors.forename: Duncan
authors.initials: D
authors.lastname: Wyncoll
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use*; D006801:Humans; D011486:Protein C / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated